tetano
Editor, Senior Moderator
Vaccine
. 2024 May 19:S0264-410X(24)00586-3.
doi: 10.1016/j.vaccine.2024.05.028. Online ahead of print. Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern
Ravendra Garg[SUP] 1 [/SUP], Qiang Liu[SUP] 2 [/SUP], Jill Van Kessel[SUP] 1 [/SUP], Akarin Asavajaru[SUP] 1 [/SUP], Eva-Maria Uhlemann[SUP] 1 [/SUP], Morgane Joessel[SUP] 3 [/SUP], Glenn Hamonic[SUP] 1 [/SUP], Zahed Khatooni[SUP] 1 [/SUP], Andrea Kroeker[SUP] 1 [/SUP], Jocelyne Lew[SUP] 1 [/SUP], Erin Scruten[SUP] 1 [/SUP], Paul Pennington[SUP] 1 [/SUP], William Deck[SUP] 1 [/SUP], Tracy Prysliak[SUP] 1 [/SUP], Michaela Nickol[SUP] 1 [/SUP], Falko Apel[SUP] 3 [/SUP], Thomas Courant[SUP] 3 [/SUP], Alyson A Kelvin[SUP] 4 [/SUP], Andrew Van Kessel[SUP] 1 [/SUP], Nicolas Collin[SUP] 3 [/SUP], Volker Gerdts[SUP] 5 [/SUP], Wolfgang Köster[SUP] 5 [/SUP], Darryl Falzarano[SUP] 5 [/SUP], Trina Racine[SUP] 6 [/SUP], Arinjay Banerjee[SUP] 7 [/SUP]
Affiliations
The emergence and ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted the need for rapid vaccine development platforms that can be updated to counteract emerging variants of currently circulating and future emerging coronaviruses. Here we report the development of a "train model" subunit vaccine platform that contains a SARS-CoV-2 Wuhan S1 protein (the "engine") linked to a series of flexible receptor binding domains (RBDs; the "cars") derived from SARS-CoV-2 variants of concern (VOCs). We demonstrate that these linked subunit vaccines when combined with Sepivac SWE™, a squalene in water emulsion (SWE) adjuvant, are immunogenic in Syrian hamsters and subsequently provide protection from infection with SARS-CoV-2 VOCs Omicron (BA.1), Delta, and Beta. Importantly, the bivalent and trivalent vaccine candidates offered protection against some heterologous SARS-CoV-2 VOCs that were not included in the vaccine design, demonstrating the potential for broad protection against a range of different VOCs. Furthermore, these formulated vaccine candidates were stable at 2-8 °C for up to 13 months post-formulation, highlighting their utility in low-resource settings. Indeed, our vaccine platform will enable the development of safe and broadly protective vaccines against emerging betacoronaviruses that pose a significant health risk for humans and agricultural animals.
. 2024 May 19:S0264-410X(24)00586-3.
doi: 10.1016/j.vaccine.2024.05.028. Online ahead of print. Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern
Ravendra Garg[SUP] 1 [/SUP], Qiang Liu[SUP] 2 [/SUP], Jill Van Kessel[SUP] 1 [/SUP], Akarin Asavajaru[SUP] 1 [/SUP], Eva-Maria Uhlemann[SUP] 1 [/SUP], Morgane Joessel[SUP] 3 [/SUP], Glenn Hamonic[SUP] 1 [/SUP], Zahed Khatooni[SUP] 1 [/SUP], Andrea Kroeker[SUP] 1 [/SUP], Jocelyne Lew[SUP] 1 [/SUP], Erin Scruten[SUP] 1 [/SUP], Paul Pennington[SUP] 1 [/SUP], William Deck[SUP] 1 [/SUP], Tracy Prysliak[SUP] 1 [/SUP], Michaela Nickol[SUP] 1 [/SUP], Falko Apel[SUP] 3 [/SUP], Thomas Courant[SUP] 3 [/SUP], Alyson A Kelvin[SUP] 4 [/SUP], Andrew Van Kessel[SUP] 1 [/SUP], Nicolas Collin[SUP] 3 [/SUP], Volker Gerdts[SUP] 5 [/SUP], Wolfgang Köster[SUP] 5 [/SUP], Darryl Falzarano[SUP] 5 [/SUP], Trina Racine[SUP] 6 [/SUP], Arinjay Banerjee[SUP] 7 [/SUP]
Affiliations
- PMID: 38769033
- DOI: 10.1016/j.vaccine.2024.05.028
The emergence and ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted the need for rapid vaccine development platforms that can be updated to counteract emerging variants of currently circulating and future emerging coronaviruses. Here we report the development of a "train model" subunit vaccine platform that contains a SARS-CoV-2 Wuhan S1 protein (the "engine") linked to a series of flexible receptor binding domains (RBDs; the "cars") derived from SARS-CoV-2 variants of concern (VOCs). We demonstrate that these linked subunit vaccines when combined with Sepivac SWE™, a squalene in water emulsion (SWE) adjuvant, are immunogenic in Syrian hamsters and subsequently provide protection from infection with SARS-CoV-2 VOCs Omicron (BA.1), Delta, and Beta. Importantly, the bivalent and trivalent vaccine candidates offered protection against some heterologous SARS-CoV-2 VOCs that were not included in the vaccine design, demonstrating the potential for broad protection against a range of different VOCs. Furthermore, these formulated vaccine candidates were stable at 2-8 °C for up to 13 months post-formulation, highlighting their utility in low-resource settings. Indeed, our vaccine platform will enable the development of safe and broadly protective vaccines against emerging betacoronaviruses that pose a significant health risk for humans and agricultural animals.